South San Francisco, CA, Jan 26, 2013 - (ACN Newswire) - Cytokinetics, Incorporated (NASDAQ: CYTK), announced today that it has received a notice from The Nasdaq Stock Market ("Nasdaq") confirming that for the last 10 consecutive business days, the closing bid price of the Company's common stock has been at $1.00 per share or greater. Accordingly, the Company has regained compliance with the minimum $1.00 bid price per share requirement.
As previously reported, the Company received notice from Nasdaq on June 18, 2012 that the Company's common stock had failed to maintain a minimum bid price of $1.00 over the previous 30 consecutive business days as required by the Listing Rules of The Nasdaq Stock Market. On December 18, 2012, the Company transferred its listing to the Nasdaq Capital Market and Nasdaq provided the Company until June 17, 2013 to achieve compliance with the minimum $1.00 bid price per share requirement.
Nasdaq has informed the Company that this matter is now closed.
Cytokinetics is a clinical-stage biopharmaceutical company focused on the discovery and development of novel small molecule therapeutics that modulate muscle function for the potential treatment of serious diseases and medical conditions. Cytokinetics' lead drug candidate from its cardiac muscle contractility program, omecamtiv mecarbil, is in Phase II clinical development for the potential treatment of heart failure. Amgen Inc. holds an exclusive license worldwide (excluding Japan) to develop and commercialize omecamtiv mecarbil and related compounds, subject to Cytokinetics' specified development and commercialization participation rights. Cytokinetics is independently developing tirasemtiv, a skeletal muscle activator, as a potential treatment for diseases and conditions associated with aging, muscle wasting or neuromuscular dysfunction. Tirasemtiv is currently the subject of a Phase II clinical trials program and has been granted orphan drug designation and fast track status by the U.S. Food and Drug Administration and orphan medicinal product designation by the European Medicines Agency for the potential treatment of amyotrophic lateral sclerosis, a debilitating disease of neuromuscular impairment in which treatment with tirasemtiv produced potentially clinically relevant pharmacodynamic effects in Phase II trials. All of these drug candidates have arisen from Cytokinetics' muscle biology focused research activities and are directed towards the cytoskeleton. The cytoskeleton is a complex biological infrastructure that plays a fundamental role within every human cell. Additional information about Cytokinetics can be obtained at www.cytokinetics.com .
This press release contains forward-looking statements for purposes of the Private Securities Litigation Reform Act of 1995 (the "Act"). Cytokinetics disclaims any intent or obligation to update these forward-looking statements, and claims the protection of the Act's safe harbor for forward-looking statements. Examples of such statements include, but are not limited to, statements relating to the properties and potential benefits of Cytokinetics' drug candidates and potential drug candidates. Such statements are based on management's current expectations, but actual results may differ materially due to various risks and uncertainties, including, but not limited to, potential difficulties or delays in the development, testing, regulatory approval and production of Cytokinetics' drug candidates and potential drug candidates that could slow or prevent clinical development or product approval, including risks that current and past results of clinical trials or preclinical studies may not be indicative of future clinical trials results and that Cytokinetics' drug candidates and potential drug candidates may have unexpected adverse side effects or inadequate therapeutic efficacy. For further information regarding these and other risks related to Cytokinetics' business, investors should consult Cytokinetics' filings with the Securities and Exchange Commission.
Jodi L. Goldstein
Manager, Marketing & Corporate Communications
This announcement is distributed by Thomson Reuters on behalf of Thomson Reuters clients.
The owner of this announcement warrants that:
(i) the releases contained herein are protected by copyright and other applicable laws; and
(ii) they are solely responsible for the content, accuracy and originality of the information contained therein.
Source: Cytokinetics, Inc. via Thomson Reuters ONE
Topic: Press release summary
From the Asia Corporate News Network
Copyright © 2015 ACN Newswire. All rights reserved. A division of Asia Corporate News Network.
|Cytokinetics, Inc. |
|Dec 23, 2014 21:00 HKT|
|Cytokinetics and Astellas Announce Expansion of Collaboration for Development of CK-2127107 in Spinal Muscular Atrophy and Other Neuromuscular Indications|
|Dec 6, 2014 07:00 HKT|
|Cytokinetics Announces Presentations Relating to Tirasemtiv and Effects on Respiratory Muscle Function at International Symposium on ALS/MND|
|Dec 2, 2014 08:30 HKT|
|Cytokinetics Announces Presentations Relating to Tirasemtiv at the 25th International Symposium on ALS/MND|
|Nov 27, 2014 07:35 HKT|
|Cytokinetics to Participate in the 26th Annual Piper Jaffray Healthcare Conference|
|Nov 11, 2014 08:50 HKT|
|Cytokinetics' President & CEO Robert Blum Receives 2014 Lou Gehrig Iron Horse Award From ALS Therapy Development Institute|
|Oct 31, 2014 10:35 HKT|
|Cytokinetics, Incorporated Reports Third Quarter 2014 Financial Results|
|Oct 28, 2014 07:25 HKT|
|Cytokinetics Provides Development Program Update for Omecamtiv Mecarbil|
|Oct 21, 2014 08:25 HKT|
|Cytokinetics Provides Development Program Update for Tirasemtiv|
|Oct 17, 2014 08:40 HKT|
|Cytokinetics to Announce Third Quarter Results on October 30, 2014|
|Oct 14, 2014 07:50 HKT|
|Cytokinetics Announces Development Program Update for CK-2127107|
|More news >>|